Yondelis (trabectedin)

About PharmaMar

Founded in 1986, PharmaMar's mission is to harness marine biodiversity to create life-changing oncology therapies. Its key achievement is the development and global commercialization of Yondelis® (trabectedin), a first-in-class drug for soft tissue sarcoma and ovarian cancer, which provides a revenue foundation. The company's strategy leverages its proprietary marine discovery platform to build a sustainable pipeline of novel small molecules, focusing on areas of high unmet need in oncology. PharmaMar operates as a fully integrated entity, controlling the entire process from research to sales.

About PharmaMar

Founded in 1986, PharmaMar's mission is to harness marine biodiversity to create life-changing oncology therapies. Its key achievement is the development and global commercialization of Yondelis® (trabectedin), a first-in-class drug for soft tissue sarcoma and ovarian cancer, which provides a revenue foundation. The company's strategy leverages its proprietary marine discovery platform to build a sustainable pipeline of novel small molecules, focusing on areas of high unmet need in oncology. PharmaMar operates as a fully integrated entity, controlling the entire process from research to sales.

About Pharma Mar

Pharma Mar's mission is to discover and develop novel cancer therapies derived from the chemical diversity of marine organisms. Its key achievement is the successful global commercialization of Yondelis® (trabectedin), a first-in-class marine-derived drug approved for soft tissue sarcoma and ovarian cancer, validating its unique platform. The company's strategy focuses on leveraging its proprietary marine biology and chemistry expertise to advance a deep pipeline of drug candidates, while exploring new indications and combinations for its existing assets. This integrated approach, from discovery to manufacturing and commercialization, aims to deliver long-term growth in the oncology market.

Therapeutic Areas

Other Soft Tissue Sarcoma Drugs